Your SlideShare is downloading. ×
Fake antimalarials and public health
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Fake antimalarials and public health

961
views

Published on

Conference on Health and Social Protection: Meeting the needs of the poor, 09-10 October 2008 …

Conference on Health and Social Protection: Meeting the needs of the poor, 09-10 October 2008
www.povill.com

Published in: Health & Medicine, Business

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
961
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
31
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1.
    • Paul Newton
    • Centre for Tropical Medicine, University of Oxford, UK
    • and
    • Wellcome Trust-Mahosot Hospital-Oxford Tropical Medicine Research Collaboration, Mahosot Hospital, Lao PDR
    Fake antimalarials and public health
  • 2. Recent Reports of Fake Antimalarials
      • * Chloroquine
      • * Quinine
      • * Tetracycline/Doxycycline
      • * Sulphadoxine-pyrimethamine
      • * Metakelfin TM
      • * Mefloquine
      • * Halofantrine
      • * ? Primaquine
      • * Artesunate
      • * Intramuscular and oral artemether
      • * Dihydroartemisinin
      • * Dihydroartemisinin-piperaquine
    Not faked ? * Artemether-lumefantrine * Atovaquone-proguanil * iv/im artesunate
  • 3. Definitions
    • Vary between countries and organisations
    • WHO definitions:
    • Counterfeit “a pharmaceutical product that is deliberately and fraudulently mislabeled with respect to identity and/or source”
    • Substandard “a pharmaceutical product with genuine packaging with incorrect quantity of ingredient (not deliberate)”
  • 4. Fake Cinchona Bark 17 th C Europe Fake Quinine London 1829 Physicians chastising a drug seller 13 th C Arabia
  • 5.
    • Avoidable sickness and death
    • Economic loss to patients & their families, health systems and genuine producers
    • Loss of confidence in key medicines
    • Loss of confidence in health facilities and health staff
    • Burden for drug regulatory authorities
    • Sub-therapeutic amounts of active ingredients - drug resistance
    • Unexpected adverse effects from harmful ‘wrong’ ingredients
    CONSEQUENCES of FAKE DRUGS
  • 6. Artesunate
    • Developed in China
    • Vital antimalarial in SE Asia
    • Without which we may have malaria that cannot be treated at a an affordable cost
  • 7. Fake artesunate in mainland SE Asia
    • 2000-2001
    • 38 % of shop bought artesunate was counterfeit, containing no active drug
    • One NGO bought 100,000 tablets in one shop
    • 2002-2003
    • 53% of shop bought artesunate was counterfeit
    There are ~ 2 x 10 6 cases of P. falciparum /year in WPRO - in ‘untreated’ non-immunes the excess mortality will be considerable
  • 8.  
  • 9. Genuine Hologram Fake Artesunate ‘Type 8’
  • 10. Genuine Hologram Fake Artesunate ‘Type 10’
  • 11. Traces of artesunate
    • Recent samples from the Thai/Burma border contain 3-10 mg artesunate per tablet (genuine tablet ~ 50mg artesunate)
    • May engender artemisinin resistance - which has started to appear on Thai/Cambodian border
  • 12. Fake artesunate ‘wrong’ ingredients
    • Paracetamol
    • Sulphadoxine
    • Pyrimethamine
    • Dimethylfumarate
    • Erythromycin A-F & anhydroerythromycin
    • Erucamide
    • Safrole
    • Artemisinin
    • Metamizole
    • Chloramphenicol
    • Metronidazole
    • Chloroquine
    • Sulphamethoxazole
  • 13. An under appreciated Asian public health disaster * Malaria remains a problem in SE Asia, but we have the tools for control * Counterfeit artesunate MUST be a major risk for death and an impediment to malaria control * Despite 6 years of awareness - situation deteriorating and little action despite severe danger to public health * How many additional deaths - thousands ?
  • 14. INTERPOL/WPRO Investigation
    • Northern temperate pollen with plants like firs, pines, cypresses, sycamores, alders, worm wood, willows, elms, and numerous fern spores present
    • Flora suggests possible source in southern China near the mountains bordering Burma and/or northernmost Viet Nam
  • 15. Debris, including Juglans pollen charcoal fragments
  • 16. Dermatophagoides mite nymph
  • 17. Valid batch numbers, stickers, multiple wrong AIs, calcite Invalid batch numbers, holograms, subtherapeutic artesunate
  • 18.
    • INTERPOL presented the evidence to the Ministry of Public Security, People’s Republic of China - who acted very quickly with a criminal investigation and arrests
    • Seized 24,000 of 240,000 blisterpacks traded by those arrested
    • Enough to allow 240,000 adults to die
    WANTED
  • 19. Genuine Hologram Fake Artesunate ‘Type 15’ Similar to Type 10 - found only in N Burma and N Laos (Westerly trade route)
  • 20.  
  • 21. Fake artemisinin derivatives in Africa
  • 22.
    • Enormous effort has been invested in determining optimum therapy for diseases such as malaria
    • Many worthwhile competing public health priorities…but…
    • Little point in doing clinical trials if insufficient effort is invested in ensuring that the drugs used in clinical practice are of good quality
  • 23. What can be done ?
    • Support for the drug regulatory authorities…
    • without effective DRAs most interventions cannot work
    • Building of sustainable links between country DRAs, police, forensic scientists, criminal analysts, WHO and INTERPOL
    • Research on prevalence of poor quality drugs and efficacy of interventions
  • 24. What can be done ?
    • Education of health workers and patients
    • Provision of inexpensive, available key antimalarial drugs - undercut the counterfeiters
    • Remove artemisinin derivative monotherapies as free accessible ACTs become available
    • Political will to tackle these problems
  • 25.  
  • 26. Acknowledgements The laboratories and their staff The Government of the People’s Republic of China Food and Drug Quality Control Centre & Food & Drug Department, Lao PDR Guilin Pharmaceutical Co. Ltd, China The Natural History Museum, London and Wolfson College, Oxford, UK David Pizzanelli, Mayfong Mayxay, Bryan Watt, Arjen Dondorp, Frank Smithuis, François Nosten, Lucy Paiphun, Aung Pyae Phyo, Khin Mg Lwin, Rose McGready, Shunmay Yeung, Chongkham Phonekeo, Christopher Curtis, Sue Lee, Nicholas Day, Nicholas White and anonymous collectors for their help and advice Funded by Wellcome Trust of Great Britain, the participating institutions and the United States Agency for International Development through US Pharmacopeia
  • 27.
    • Facundo M Fernández, Aline Plançon, Dallas C Mildenhall, Michael D Green, Li Ziyong, Eva Maria Christophel,
    • Souly Phanouvong, Stephen Howells, Eric McIntosh, Paul Laurin, Nancy Blum, Christina Y Hampton, Kevin Faure,
    • Leonard Nyadong, CWR Soong , Budiono Santoso, Wang Zhiguang, John Newton, Kevin Palmer
    • Centre for Tropical Medicine, Churchill Hospital, University of Oxford, UK
    • School of Chemistry & Biochemistry, Georgia Institute of Technology, USA
    • Intellectual Property Crime Unit, INTERPOL, France
    • GNS Science, New Zealand
    • Division of Parasitic Diseases, CDC, USA
    • Intellectual Property Division, Ministry of Public Security, Beijing, People’s Republic of China
    • Western Pacific Regional Office of the World Health Organization, The Philippines
    • United States Pharmacopeia, USA
    • Therapeutic Goods Administration, Australia,
    • Royal Canadian Mounted Police, Forensic Laboratory Services, Canada